Analysts forecast the global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022. The latest trend gaining momentum in the market is growing popularity of drugs over surgeries.
- Advertising -
Although pharmacological therapies for acromegaly treatment have been there for more than a decade, the demand from individuals for these non-surgical options is increasing on a regular basis.
Access Sample Report at www.reportsnreports.com/contacts/r…aspx?name=1346567.
- Advertising -
The prime reason for the shift in choice can be attributed to low success rates of acromegaly surgeries. For instance, as per the NIH, in a study involving total 62 subjects, 31 subjects were treated by transsphenoidal surgery, and four subjects were cured.
Out of these 31 subjects treated with transsphenoidal surgery, post-operative anterior pituitary hormone deficiency was seen in 10 subjects, and diabetes insipidus got developed in one subject.
Major key players in the global acromegaly and gigantism drugs market: Ipsen, Novartis, and Pfizer
According to the acromegaly and gigantism drugs market report, one of the major drivers for this market is Strong pipeline. The presence of a large number of molecules in pipeline represents significant opportunities for market growth.
Around 42.86% of the total pipeline molecules for acromegaly and gigantism are in Phase III stage of development and are expected to be launched during the forecast period. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition.
For instance, octreotide capsules by Chiasma and Pasireotide long-acting release (LAR) by Novartis for individuals with acromegaly who are inadequately treated with somatostatin analogs, and combination therapy of lanreotide autogel and pegvisomant by Ipsen are in Phase III stage of development for the treatment of acromegaly.
Further, the acromegaly and gigantism drugs market report states that one of the major factors hindering the growth of this market is Difficulty in diagnosis. In the last two decades, numerous important advancements took place in the domain such as the emergence of assays with improved sensitivity for IGF-1 and GH, development of automated software for evaluating physical changes associated with the disease, and widespread pituitary examination using magnetic resonance imaging (MRI).
Despite all these advancements, acromegaly remains clinically under-diagnosed.
Access report at www.reportsnreports.com/purchase.aspx?name=1346567.
Key questions answered in this report:
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
Few Points from List of Exhibits Provided in Global Acromegaly and Gigantism Drugs 2018-2022:
Exhibit 1: Parent Market
Exhibit 2: Global Acromegaly and Gigantism Drugs Market
Exhibit 3: Market Characteristics
Exhibit 4: Market Segments
Exhibit 5: Market Definition - Inclusions and Exclusions Checklist
Exhibit 6: Market Size 2017
Exhibit 7: Validation Techniques Employed For Market Sizing 2017
Exhibit 8: Global Acromegaly and Gigantism Drugs Market 2017-2022 ($ Mn)
Exhibit 9: Global Acromegaly and Gigantism Drugs Market: Year-Over-Year (Yoy) Growth 2018-2022 (%)
Exhibit 10: Five Forces Analysis 2017
Exhibit 11: Five Forces Analysis 2022
Exhibit 12: Bargaining Power of Buyers
Exhibit 13: Bargaining Power of Suppliers
Exhibit 14: Threat of New Entrants
Exhibit 15: Threat of Substitutes
Exhibit 16: Threat of Rivalry
Exhibit 17: Market Condition - Five Forces 2017
Exhibit 18: Pipeline Landscape by Development Phase
Exhibit 19: Key Clinical Trials For Global Acromegaly and Gigantism Drugs Market
Exhibit 20: Segmentation of Global Acromegaly and Gigantism Drugs Market by Drug Class 2017-2022 (%)